Systems-based identification of the Hippo pathway for promoting fibrotic mesenchymal differentiation in systemic sclerosis

By sjmartinez • January 5, 2024

Ma F, Tsou PS, Gharaee-Kermani M, Plazyo O, Xing X, Kirma J, Wasikowski R, Hile GA, Harms PW, Jiang Y, Xing E, Nakamura M, Ochocki D, Brodie WD, Pillai S, Maverakis E, Pellegrini M, Modlin RL, Varga J, Tsoi LC, Lafyatis R, Kahlenberg JM, Billi AC, Khanna D, Gudjonsson JE. Systems-based identification of the Hippo pathway for promoting fibrotic mesenchymal differentiation in systemic sclerosis. Nat Commun. 2024 Jan 3;15(1):210. doi: 10.1038/s41467-023-44645-6. PMID: 38172207.

Tags: Infectious Diseases, Publications

A Double-blind Randomized Trial of Oral Chlorhexidine Gluconate for Treatment of Oral Staphylococcus aureus Colonization in Healthy Children

Liu L, Launer B, Flores E, Tchakalian G, Kreiswirth B, Bolaris M, Kim T, Young KD, Miller LG. A Double-blind Randomized Trial of Oral Chlorhexidine[...]

Comparing sampling approaches for assessing sub-national vaccination coverage: a pilot study in Central African Republic and the Democratic Republic of Congo

Kasonga JN, Hoff NA, Merritt S, Fandema E, Nkamba DM, Zanga-Goumet HE, Bobo E, Tangney S, Mafuta E, Bangelesa F, Babakazo P, Kokolomami J, Stahley[...]

Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19

Glascock A, Maguire C, Phan HV, Lydon EC, Schaenman J, Calfee CS, Melamed E, Greenland J, Corry DB, Kheradmand F, Baden LR, Sekaly R, McComsey[...]